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Abstract The REFLEX study (NCT00404352) estab-
lished that subcutaneous (sc) interferon (IFN) b-1a reduced
the risks of McDonald MS (2005 criteria) and clinically
definite multiple sclerosis (CDMS) in patients with a first
clinical demyelinating event suggestive of MS. The aim of
this subgroup analysis was to assess the treatment effect of
sc IFN b-1a in patient subgroups defined by baseline dis-
ease and demographic characteristics (age, sex, use of
steroids at the first event, classification of first event as
mono- or multifocal, presence/absence of gadolinium-
enhancing lesions, count of \9 or C9 T2 lesions), and by
diagnosis of MS using the revised McDonald 2010 MS
criteria. Patients were randomized to the serum-free for-
mulation of IFN b-1a, 44 lg sc three times weekly or once
weekly, or placebo, for 24 months or until diagnosis of
CDMS. Treatment effects of sc IFN b-1a on McDonald
2005 MS and CDMS in the predefined subgroups were
similar to effects found in the intent-to-treat population.
McDonald 2010 MS was retrospectively diagnosed in
37.7 % of patients at baseline. Both regimens of sc IFN
b-1a significantly reduced the risk versus placebo of
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McDonald 2005 MS and CDMS, irrespective of McDonald
2010 status at baseline (risk reductions between 29 and
51 %). The effect of sc IFN b-1a was not substantially
influenced by baseline patient demographic and disease
characteristics, or baseline presence/absence of McDonald
2010 MS.
Keywords Interferon beta  First clinical demyelinating
event  Clinically isolated syndrome  McDonald MS 
Clinically definite MS
Introduction
The first presentation of relapsing multiple sclerosis (MS) is
the occurrence of an acute first clinical demyelinating event.
The risk of new clinical and/or magnetic resonance imaging
(MRI) events can be determined by a number of findings, such
as the presence of specific oligoclonal bands in the cerebro-
spinal fluid, subclinical abnormalities in visual evoked
potentials, the number of T2 lesions, the number of gadolin-
ium-enhancing (Gd?) lesions and the type of clinical pre-
sentation (monofocal or multifocal) [1–7]. Occasionally,
lesions within the central nervous system (CNS) characteristic
of MS may be detected by MRI in the absence of clinical
symptoms (radiologically isolated syndrome) [8].
The McDonald criteria for the diagnosis of MS have been
continually reviewed and updated as necessary since their
initial publication in 2001 [9, 10]. The most recent version of
the criteria (McDonald 2010 [11]) permits the diagnosis of MS
at the time of the first clinical demyelinating event without a
requirement for a second attack, provided certain MRI find-
ings are met. This means that some patients who would not
have been diagnosed as having MS at the time of the first
attack (clinically isolated syndrome) using the 2005 criteria
would now be diagnosed as having MS on the basis of having
both one or more Gd? lesions (not related to the attack) and
non-enhancing lesions on MRI.
The REFLEX (REbif FLEXible dosing in early MS;
clinicaltrials.gov identifier NCT00404352) trial demon-
strated that, in patients with a first clinical demyelinating
event at high risk of conversion to MS, interferon (IFN) b-
1a, 44 lg subcutaneously (sc) three times weekly (tiw) or
once weekly (qw), significantly delayed conversion to
McDonald MS (defined by the 2005 criteria) and clinically
definite MS (CDMS), and significantly reduced MRI
measures of disease activity versus placebo over 24 months
[12]. The efficacy of tiw dosing was significantly greater
than that of qw dosing for conversion to McDonald MS and
MRI outcomes [12].
This paper will report the result of analyses of pre-
specified patient subgroups in the REFLEX trial. The
patient subgroups included those factors used to balance
the population during randomization and others that have
previously been identified as risk factors for McDonald MS
or CDMS. With the revision to the McDonald guidelines
[11], it was also important to establish whether sc IFN b-1a
was effective in the subgroup of patients who would still
have been classified as not having MS by the updated
criteria, and also to monitor the time to the second clinical
event in patients who would have been diagnosed as
already having MS at the time of their inclusion in the
REFLEX study.
Methods
The full methodology of this trial has been published
previously [12]. Briefly, patients with a first clinical
demyelinating event suggestive of MS were randomized
1:1:1 to the serum-free formulation of IFN b-1a, 44 lg sc
tiw or qw, or placebo, for 24 months or until a diagnosis of
CDMS. An independent adjudication committee was
responsible for assessing the eligibility of all patients,
confirming or reclassifying each patient’s first event as
mono- or multifocal and reviewing all relapses that con-
tributed to a diagnosis of CDMS. This committee was
blinded to treatment group and comprised neurologists and
a neuroradiologist with expertise in MS. The reporting and
evaluation of relapses were continuous and independent of
scheduled visits. A relapse was defined as new or wors-
ening neurological symptoms, in the absence of fever,
lasting for at least 24 h, accompanied by an objective
change in the relevant (i.e., symptomatic) functional sys-
tem, and preceded by 30 days or more of clinical stability
or improvement. MRI scans were evaluated centrally at the
VU Medical Center, Amsterdam, the Netherlands. The
study was undertaken in compliance with the Declaration
of Helsinki and standards of Good Clinical Practice
according to the International Conference on Harmonisa-
tion of Technical Requirements for Registration of Phar-
maceuticals for Human Use. Before initiation of the trial at
each centre, the relevant institutional review board or
independent ethics committee reviewed and approved the
trial protocol, patient information leaflet, informed consent
forms, and investigator brochure.
The predefined subgroups in this analysis were those used
to stratify the randomization process: age\30 or C30 years,
use of steroids at first attack, multi- or monofocal presentation
of first clinical demyelinating event, presence or absence of
Gd? lesions at baseline. Other predefined subgroups were sex
and the presence of\9 or C9 T2 lesions at baseline.
In a post hoc analysis, a simulated retrospective diag-
nosis at baseline of dissemination in time and space
according to the McDonald 2010 MS criteria was con-
ducted for each patient. Evidence of dissemination in time
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was defined as the simultaneous presence of Gd? and non-
enhancing lesions (with the exception of patients with
brainstem syndromes). Dissemination in space was defined
as the presence of C1 T2 lesions in C2 of three MS-typical
regions of the CNS; in the original REFLEX MRI analysis,
spinal cord location was not assessed and, therefore, only
the juxtacortical, periventricular, and infratentorial regions
were analyzed [12]. Patients were divided into McDonald
2010-positive and -negative subgroups.
All subgroup analyses were considered to be
exploratory.
Statistical analyses
The primary endpoint of the REFLEX study was time to
conversion to McDonald MS as defined by the 2005 ver-
sion of the criteria [10]. The main secondary endpoint was
time to conversion to CDMS. As described previously [12],
the probability of patients remaining event free over time
(from randomization) in each of the three treatment groups
was estimated using the nonparametric Kaplan–Meier
method for the primary and main secondary endpoints. The
hazard ratios (HRs) for between-group comparisons with
corresponding two-sided 95 % confidence intervals (CIs)
in the prespecified subgroups were estimated using an
unadjusted univariate Cox’s proportional hazard model
with treatment as the only covariate. p values for the
comparison between treatment groups within each sub-
group were calculated using the same model. Treatment
effects within McDonald 2010 MS status strata were ana-
lyzed post hoc using Cox’s proportional hazard regression
models, with treatment as a covariate.
Results
The intent-to-treat (ITT) population comprised all 517
patients randomized to treatment. As previously described,
baseline demographic and disease characteristics were
similar across treatment groups [12]. Baseline character-
istics of the ITT population, stratified by retrospective
McDonald 2010 status, are summarized in Table 1.
Conversion to MS in subgroup populations
McDonald MS 2005
Subgroups defined by patient demographics (age \30 vs.
C30 years), sex (female vs male), and steroid use during
the first clinical demyelinating event (yes vs. no) did not
increase the risk of McDonald 2005 MS (p [ 0.05 for all
three covariates). This is reflected in the proportion of
placebo-treated patients with McDonald 2005 MS at
2 years that were similar (range 83–89 %; Fig. 1a) across
these subgroups.
There was a significantly increased risk of McDonald
2005 MS in patient subgroups with evidence of more
severe disease activity at baseline (Fig. 1b): C1 Gd?
lesions versus no Gd? lesions, C9 T2 lesions vs. \9 T2
lesions, and in patients with multifocal versus monofocal
presentation of the first clinical demyelinating event
(p \ 0.05 for all three covariates). This is reflected in the
proportion of placebo-treated patients with McDonald 2005
MS at 2 years (range 62–97 %; Fig. 1b).
In general, the treatment effects of sc IFN b-1a were
similar between predefined subgroups and similar to those
found in the overall ITT population (Fig. 1a). A signifi-
cant treatment effect of sc IFN b-1a tiw versus placebo
was found in all subgroups apart from the subgroup of
male patients. A significant treatment effect of sc IFN b-
1a qw versus placebo was observed in the following
subgroups: age C30 years, female patients, patients who
used steroids for the first clinical event, patients with
multifocal presentation, patients with C1 Gd? lesion at
baseline, and patients with \9 and C9 T2 lesions at
baseline (Fig. 1a, b).












Age, years, mean (SD) 30.7 (8.2) 31.8 (8.3) 28.9 (7.6)









277 (53.6) 192 (59.6) 85 (43.6)
Steroid use at first clinical
demyelinating event,
n (%)
365 (70.6) 239 (74.2) 126 (64.6)
Number of T1 Gd? lesions,
mean (SD)
1.3 (2.9) 0.1 (0.8)b 3.3 (3.9)
Presence of Gd? lesions at
baseline, n (%)
213 (41.2) 18 (5.6)b 195 (100)
Number of T2 lesions,
mean (SD)
22.3 (20.0) 17.6 (15.7)b 29.8 (23.4)
Presence of C9 T2 lesions
at baseline, n (%)
377 (72.9) 201 (63.0)b 174 (89.2)
Gd? gadolinium-enhancing, MRI magnetic resonance imaging, MS
multiple sclerosis, SD standard deviation
a According to the adjudication committee
b n = 319
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CDMS
In subgroups defined by patient demographics and steroid
treatment, estimates of CDMS in placebo-treated patients
at 2 years were in the range of 34–41 % (Fig. 2a). In
subgroups defined by MRI findings at baseline, estimates
of CDMS at 2 years were in the range of 31–46 % in
placebo-treated patients (Fig. 2b). None of the predefined
tiw qw placebo
Treatment effect
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Number of Gd+ lesions at baseline
Number of T2 lesions at baseline
Fig. 1 Analysis of the time to McDonald 2005 MS according to
prespecified subgroups of a patient demographics and steroid
treatment, and b MRI findings at the first clinical demyelinating
event (ITT population; n = 517). Footnote a p value calculated by a
multivariate Cox proportional hazards model. CI confidence interval,
Gd? gadolinium-enhancing, IFN interferon, ITT intent-to-treat, KM
Kaplan–Meier, MRI magnetic resonance imaging, MS multiple
sclerosis, qw once weekly, sc subcutaneous, tiw three times weekly
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baseline subgroups examined showed an effect on time to
CDMS in the Cox proportional hazards regression model
(p [ 0.05 in all cases).
As previously reported [12], time to CDMS compared
with placebo was significantly reduced by both dose-fre-
quencies of sc IFN b-1a, with no significant difference
between tiw and qw dosing. The treatment effects of sc IFN
b-1a in the predefined subgroups were similar to those in
the ITT population (Fig. 2).
Post hoc analysis of McDonald 2010 MS status
at baseline
Retrospective application of the McDonald 2010 criteria
found that 195/517 (37.7 %) of patients in the ITT popu-
lation in REFLEX would have been classified as having
had MS at baseline (Table 2).
Baseline characteristics of patients with retrospective
McDonald 2010 diagnosis were generally similar to those
of the ITT population, with the expected exceptions of a
higher mean number of Gd? and T2 lesions and a lower
proportion of patients with monofocal presentation
(Table 1).
Effect on risk of McDonald 2005 MS
In placebo-treated patients, the risk of McDonald 2005 MS
at 2 years was 79 % in patients who were McDonald 2010
MS-negative at baseline (Fig. 3a) and 97 % in patients who
were McDonald 2010 MS-positive at baseline (Fig. 3b),
compared with 86 % in all patients. The risk of McDonald
2005 MS was significantly higher in patients who were
McDonald 2010 MS-positive compared with McDonald
2010 MS-negative at baseline (covariate effect for
McDonald 2010 MS-positive vs. -negative at baseline; HR
2.25, 95 % CI 1.83–2.77; p \ 0.001).
The treatment effect of sc IFN b-1a versus placebo on
McDonald 2005 MS was significant in patients who were
positive (risk reductions: tiw, 46 %; qw, 34 %) and nega-
tive (risk reductions: tiw, 51 %; qw, 29 %) for McDonald
2010 MS at baseline (Fig. 4). There was a significantly
greater treatment effect of tiw versus qw in patients neg-
ative for McDonald 2010 MS at baseline, with a similar but
non-significant trend in patients positive for McDonald
2010 MS.
Effect on risk of CDMS
There was a borderline, non-significant increased risk of
developing CDMS in McDonald 2010-positive versus -
negative patients (covariate effect for McDonald 2010 MS-
positive vs. -negative at baseline; HR 1.38, 95 % CI
0.97–1.95; p = 0.0704). This is reflected in placebo-treated
patients, in whom the risk of CDMS at 2 years was 32 % in
those McDonald 2010 MS-negative (Fig. 5a) and 46 % in
those McDonald 2010 MS-positive (Fig. 5b) at baseline
(corresponding proportions at 1 year: McDonald
2010-negative 19 %, McDonald 2010-positive 29 %).
The treatment effect of sc IFN b-1a tiw versus placebo
on time to CDMS was significant in patients positive or
negative for McDonald 2010 MS at baseline (risk reduc-
tions: 56 and 47 %, respectively; Fig. 6). The treatment
effect of sc IFN b-1a qw versus placebo on time to CDMS
was significant in patients who were McDonald 2010 MS-
positive at baseline, but not in those who were McDonald
2010 MS-negative (risk reductions: 59 and 36 %, respec-
tively). There was no significant difference in treatment
effect of tiw versus qw, irrespective of McDonald 2010 MS
status at baseline.
Discussion
Previous studies of patients with a first clinical demyelin-
ating event suggestive of MS have found that certain
patient characteristics, such as younger age, more active
disease as assessed by MRI, and steroid use during the first
event, are predictive of CDMS [7, 13]. In the REFLEX
study, the primary outcome was McDonald 2005 MS.
Multifocal presentation, the presence of Gd? lesions and
C9 T2 lesions at baseline predicted a higher risk of
McDonald 2005 MS at 2 years. Age, sex, and steroid use
during the first clinical demyelinating event did not predict
a higher risk of McDonald 2005 MS at 2 years. In contrast
to previous studies, none of the subgroups examined pre-
dicted a higher risk of CDMS at 2 years, although there
was a trend towards an increased risk in patients with
multifocal presentation and presence of Gd? lesions and
C9 T2 lesions at baseline, similar to that observed for
conversion to McDonald 2005 MS.
The treatment effect on McDonald 2005 MS with both
dose-frequencies of sc IFN b-1a in the predefined sub-
groups was broadly consistent with the findings of the
REFLEX ITT analysis [12]. This suggests that the treat-
ment effect of sc IFN b-1a is not dependent on demo-
graphic or disease characteristics. An interesting exception
to this was the reduced treatment effect in male compared
to female patients. However, the small number of male
patients in each treatment group might have limited the
ability to detect a significant treatment effect.
The treatment effect of sc IFN b-1a on McDonald 2005
MS was generally greater with tiw than with qw dosing, the
difference reaching statistical significance in several sub-
groups. This is consistent with the clear additional benefit
of tiw over qw dose-frequency on McDonald 2005 MS, as
seen in the ITT population [12].
494 J Neurol (2014) 261:490–499
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The McDonald criteria for the diagnosis of MS have
been revised since the REFLEX study started. The changes
to the criteria potentially allow the earlier diagnosis of MS
such that, using a retrospective diagnosis of McDonald
2010 MS, over a third of the patients enrolled in REFLEX
already had MS. An important question is whether
tiw qw placebo
Treatment effect
















































































Steroid use during first clinical demyelinating event
tiw qw placebo
Treatment effect



































































0 0.5 1 1.5 2
B
Classification of first clinical demyelinating event
Number of Gd+ lesions at baseline
Number of T2 lesions at baseline
Fig. 2 Analysis of the time to CDMS according to prespecified
subgroups of a patient demographics and steroid treatment, and
b MRI findings at the first clinical demyelinating event (ITT
population; n = 517). Footnote a p value calculated by a multivariate
Cox proportional hazards model. CI confidence interval, CDMS
clinically definite multiple sclerosis, Gd? gadolinium-enhancing, IFN
interferon, ITT intent-to-treat, KM Kaplan–Meier, MRI magnetic
resonance imaging, qw once weekly, sc subcutaneous, tiw three times
weekly
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excluding patients positive for McDonald 2010 MS at
baseline would have affected the primary and main clinical
secondary endpoints of the REFLEX study. In patients who
were McDonald 2010 MS-positive at baseline, the endpoint
of McDonald 2005 MS potentially provides a useful
composite endpoint of new MRI lesions or a relapse. The
baseline characteristics of patients with a retrospective
McDonald 2010 diagnosis were similar to those of the ITT
population, with the exception of a higher number of Gd?
lesions and T2 lesions, and a lower rate of monofocal
presentation. These differences were expected as the 2010
definition of dissemination in time (simultaneous detection
of Gd? and T2 lesions) meant that all patients classified as
having McDonald 2010 MS had Gd? lesions. Similarly,
the 2010 definition of dissemination in space (C1 T2
lesions in C2 of four MS-typical regions of the CNS)
selected for patients with higher numbers of T2 lesions and
wider dissemination within the CNS [11].
Retrospective diagnosis of McDonald 2010 MS at
baseline increased the risk of McDonald 2005 MS (i.e., a
greater risk of new MRI findings or relapse at some point in
the 2 years of the study) at 2 years in patients treated with
placebo. This was expected from the predefined subgroup
analyses, in which an increased risk of McDonald 2005 MS
Table 2 Baseline characteristics leading to retrospective McDonald 2010 MS diagnosis
IFN b-1a, 44 lg sc
tiw (n = 171)
IFN b-1a, 44 lg





C1 Gd? lesions at baseline and number of T2 lesions [ number of Gd?
lesions
68 (39.8) 72 (41.1) 73 (42.7)a 212 (41.0)
C1 T2 lesions in two of three locations (periventricular, juxtacortical or
infratentorial)b and/or multifocal presentation (by adjudication
committee)
144 (84.2) 148 (84.6) 139 (81.3) 431 (83.4)
Fulfilling McDonald 2010 MS criteriac (both of the above) 62 (36.3) 66 (37.7) 67 (39.2) 195 (37.7)
Data are presented as n (%)
Gd? gadolinium-enhancing, IFN interferon, MS multiple sclerosis, qw once weekly, sc subcutaneously, SD standard deviation, tiw three times
weekly
a One patient was excluded from the McDonald 2010-positive population because an additional criterion of having a greater number of T2
lesions than Gd? lesions at baseline was not met
b According to the investigator
c The McDonald 2010 MS criteria specify C1 T2 lesions in C2 of four MS-typical regions of the central nervous system; the REFLEX study did
not assess spinal cord location
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Fig. 3 Kaplan–Meier cumulative incidence curves for time to conversion to McDonald 2005 MS in patients negative (a) and positive (b) for
McDonald 2010 MS at baseline. IFN interferon, MS multiple sclerosis, qw once weekly, sc subcutaneously, tiw three times weekly
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was observed in patients with Gd? lesions or C9 T2
lesions at baseline. Both dose-frequencies of sc IFN b-1a
showed significant treatment effects versus placebo on the
risk of McDonald 2005 MS, irrespective of McDonald
2010 MS status at baseline. There was a significant dif-
ference in treatment effect between tiw and qw dosing in
patients negative for McDonald 2010 MS at baseline.
These results suggest that the primary finding of the
REFLEX study would be the same if patients positive for
McDonald 2010 MS were excluded. In other words, sc IFN
b-1a can delay McDonald MS in patients with a first
clinical demyelinating event, with evidence of a signifi-
cantly greater effect in patients receiving sc IFN b-1a tiw
versus qw. In patients who were positive for McDonald
IFN β-1a,
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Fig. 4 Conversion to McDonald 2005 MS, by McDonald 2010 MS
status at baseline. Footnote a p value calculated by a Cox proportional
hazards model, with treatment and MS status (McDonald or clinically
definite MS: yes or no) as covariates. CI confidence interval, IFN
interferon, MS multiple sclerosis, qw once weekly, sc subcutaneously,
tiw three times weekly
B
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Fig. 5 Kaplan–Meier cumulative incidence curves for time to conversion to CDMS in patients negative (a) and positive (b) for McDonald 2010
MS at baseline. CDMS clinically definite multiple sclerosis, IFN interferon, qw once weekly, sc subcutaneously, tiw three times weekly
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2010 MS at baseline, there was a trend towards a differ-
ence, albeit not significant, between tiw and qw dosing in
the treatment effect on McDonald 2005 MS.
McDonald 2010 MS status at baseline did not apparently
affect time to CDMS in patients treated with placebo, as
McDonald 2010 MS status in the post hoc analysis was not
a significant covariate in the qw versus placebo model, and
was of only borderline significance in the tiw versus pla-
cebo model. This might have been expected from the
analysis of the predefined subgroups, as there was no sig-
nificant effect of the number of Gd? or T2 lesions at
baseline on time to CDMS. The treatment effect of sc IFN
b-1a on CDMS was similar to that observed in the ITT
population, irrespective of McDonald 2010 MS status at
baseline.
The analysis of the McDonald 2010 MS-positive pop-
ulation offers some insight into the clinical efficacy of sc
IFN b-1a in the early phase of relapsing–remitting MS.
Although the REFLEX study was not powered to detect
clinical efficacy in this subgroup, both sc IFN b-1a tiw and
qw showed a significant reduction versus placebo in the
occurrence of McDonald 2005 MS (i.e., new MRI findings
or relapse) and CDMS.
The results of these subgroup analyses of data from the
REFLEX study show that the treatment effects of sc IFN b-
1a at both dose frequencies across all subgroups were
consistent with the treatment effects in the ITT population,
and that there was a clear additional benefit of tiw over qw
dose frequency for time to McDonald MS. These treatment
effects were also similar across subgroups in which patients
were stratified by retrospective diagnosis of McDonald MS
by the 2010 criteria, suggesting that had these criteria been
available at the time of study design, the main conclusions
of the REFLEX study, that sc IFN b-1a reduced the risk of
McDonald 2005 MS and CDMS in patients with a first
clinical demyelinating event, would not have been affected.
Taken together, these analyses add to the previously
reported findings of the REFLEX study, in that a consistent
treatment effect of both dosing frequencies is seen across
all patient groups, with a more robust effect of tiw over qw
dosing on McDonald 2005 MS and MRI lesion counts.
This further supports the initiation of treatment with sc IFN
b-1a at the time of the first clinical demyelinating event.
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